Clinical Trials Logo

Epithelial Ovarian Cancer clinical trials

View clinical trials related to Epithelial Ovarian Cancer.

Filter by:

NCT ID: NCT03268876 Recruiting - Clinical trials for Epithelial Ovarian Cancer

The INFLUENCE of Cytoreduction on PRO in EOC

INFLUENCE
Start date: March 3, 2021
Phase:
Study type: Observational

Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach this project aims to better define the value of cytoreduction and to use the knowledge gained to develop more individualized therapy and follow-up. This will be achieved through a translational biomedical research approach. Due to the research group's traditions clinical phenotyping, biomarker identification, and clinical trials will be the focus.

NCT ID: NCT03213964 Completed - Clinical trials for Fallopian Tube Cancer

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Start date: October 19, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary peritoneal cancer meeting one of the following minimal prior treatment requirement: - Platinum resistant: may receive FATE-NK100 as 2nd line (as 1st salvage therapy). Platinum resistant is defined as disease that has responded to initial chemotherapy but demonstrates recurrence within a relatively short period of time (< 6 months) following the completion of treatment. - Platinum sensitive: may receive FATE-NK100 as 3rd line therapy (as 2nd salvage therapy). Platinum sensitive is defined as the recurrence of active disease in a patient who has achieved a documented response to initial platinum-based treatment and has been off therapy for an extended period of time (≥ 6 months).

NCT ID: NCT03180177 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer

EHNPCTASEOC
Start date: March 1, 2018
Phase: Phase 3
Study type: Interventional

This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer . PR/SD rate, percentage of optimal debulking surgery and 3-year disease-free survival is the primary end points of this project.

NCT ID: NCT03155451 Completed - Clinical trials for Epithelial Ovarian Cancer

Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

ctDNA_EOC
Start date: August 14, 2017
Phase: N/A
Study type: Observational

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA.This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

NCT ID: NCT03106987 Completed - Clinical trials for Epithelial Ovarian Cancer

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

OReO
Start date: June 8, 2017
Phase: Phase 3
Study type: Interventional

The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer)

NCT ID: NCT03100006 Terminated - Clinical trials for Epithelial Ovarian Cancer

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

ORION-01
Start date: February 22, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety and tolerability, identify a recommended dose for expansion (RDE) / recommended phase II dose (RP2D), pharmacodynamics, and antitumor activity of Oregovomab vaccination in combination with Nivolumab as a novel combinatorial immunotherapeutic strategy in in female patients with recurrent epithelial ovarian cancer (EOC) who progressed after two or more prior lines of cytotoxic chemotherapy.

NCT ID: NCT03093155 Completed - Clinical trials for Fallopian Tube Cancer

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Start date: April 3, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.

NCT ID: NCT02952521 Completed - Clinical trials for Epithelial Ovarian Cancer

Ovarian Tumor Biopsies to Study Response to Treatments

Start date: January 25, 2017
Phase:
Study type: Observational

This is a research study to look at differences in tumor tissue from ovarian cancer patients that may help to determine response and resistance to treatments.

NCT ID: NCT02947152 Terminated - Clinical trials for Renal Cell Carcinoma

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Start date: December 1, 2016
Phase: Phase 1
Study type: Interventional

A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma

NCT ID: NCT02943317 Terminated - Clinical trials for Epithelial Ovarian Cancer

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.